ASX Announcement **29 October 2026**

Quarterly Activities Report

For the Quarter Ended 30 September 2026 (Q1 FY27)

Highlights

- **Positive European ADHD study results:** BlinkLab's first ADHD case-control study, run with Mental Care Group (MCG) in the Netherlands, achieved 82% sensitivity and 83% specificity in 208 children aged 6 to 17 years. This is believed to be the first evidence that smartphone-derived digital neurobehavioural biomarkers can detect ADHD, and forms the foundation for BlinkLab Dx2.
- **Dx2 moving towards a U.S. regulatory program:** Following the results, the Company commenced preparations for a U.S. pilot study for Dx2, to be followed by an FDA registrational study, mirroring the development pathway established for BlinkLab Dx1 in autism.
- **Former Apple Health Clinical Lead appointed to the Board:** Dr Raphael Bernier, former Clinical Lead for Mental Health at Apple Health and former Executive Director of the Seattle Children's Autism Center, joined the Board as a Non-Executive Director, strengthening clinical and commercial expertise ahead of FDA submission and U.S. launch. Dr Richard Hopkins stepped down from the Board.
- **FDA 510(k) pivotal study for Dx1 on track:** Recruitment and testing continued across leading U.S. autism centres, with the study expected to complete in Q4 CY2026, results submitted to the FDA in Q1 CY2027 and an FDA response on 510(k) clearance targeted for Q2 CY2027.
- **Broad research portfolio maturing:** Nine exploratory programs across neurodevelopment, adult neurology and treatment monitoring, with four readouts expected in Q4 CY2026 and five in CY2027.
- **Financial position:** Cash position at 30 September 2026 was ~**A$16.2** million.

BlinkLab Limited (ASX:BB1) ("BlinkLab" or the "Company"), a leading digital healthcare company focused on AI-powered diagnostics, is pleased to provide its Quarterly Activities Report and Appendix 4C for the period ended 30 September 2026 (the "Quarter" or the "Reporting Period").

Commenting on the September Quarter, BlinkLab Co-founder, CEO and Managing Director, Dr Henk-Jan Boele, stated:

"This quarter, we took the first step towards launching our second product, BlinkLab Dx2 for ADHD. Our European study delivered 82% sensitivity and 83% specificity, showing that the same technology, delivered through the same app we are taking through FDA review for autism, may also support ADHD assessment. ADHD represents a larger opportunity than paediatric autism, and Dx2 lets us build on the clinical and regulatory foundations we have already established with Dx1.

Our pivotal FDA 510(k) study for Dx1 remains our first priority and is progressing to plan. With completion of the study expected this quarter, we are also preparing for what comes after potential clearance. Raphael Bernier's appointment to the Board is a big part of that. Few people have both led one of the largest autism clinical programs in the United States and shipped clinical products at Apple scale, and his experience will be invaluable as we prepare for a specialist-first U.S. launch.

"The coming quarter will also be interesting as we expect readouts from four research programs exploring other potential opportunities: adult autism assessment, adult autism and lifestyle monitoring, early dementia detection, and ketamine treatment monitoring. These results will help us understand where else our technology may have potential."

Overview of Operations

European ADHD Study Delivers Positive Results

On 5 August 2026, the Company reported results from its European case-control study of smartphone-based digital neurobehavioural biomarkers in children aged 6 to 17 years, conducted with Mental Care Group (MCG), one of Europe's largest providers of youth mental health care.[1]

Of the 375 children recruited, those with co-occurring neurodevelopmental or psychiatric conditions, and those taking medication, were excluded to create a clearly defined ADHD group and a clean comparison group. Of the 208 children remaining, 117 had a confirmed clinical diagnosis of ADHD, established through multidisciplinary clinical review at MCG, and 91 were neurotypical controls recruited from the general community. Both arms exceeded the 50-per-arm threshold used in published meta-analyses, making the cohort one of the largest case-control datasets reported for ADHD assessment tools.

The Dx2 machine learning model correctly identified 82% of children in the ADHD group (sensitivity) and correctly classified 83% of children in the comparison group (specificity). BlinkLab's objective neurometric markers were also positively associated with subjective clinical observations in participants' diagnostic reports: the leading inattention biomarker showed a positive correlation, comparable to or greater than the agreement typically seen between parents and teachers rating the same child.

The study was completed at no cost to BlinkLab. MCG contributed clinical expertise, participant access and diagnostic review, while BlinkLab ran the smartphone assessments and data analysis.

[1] *ASX Announcement (5 August 2026) – "European ADHD Study Delivers Positive Results, Supporting Expansion of Diagnostic Platform Beyond Autism"*

BlinkLab retains ownership of the study data and all intellectual property generated. As an exploratory case-control study, it was not designed to support a regulatory submission; further prospective validation and regulatory clearance (FDA/MDR) are required before the technology could be used as an ADHD diagnostic aid.

Why ADHD Matters: Looking Forward to BlinkLab Dx2

The ADHD results are a strategic inflection point for BlinkLab. They show that the platform underpinning Dx1 is not a single-indication test, but a neurometric platform able to address more than one condition from the same 10 to 15 minute smartphone assessment.[2]

- **A larger market than paediatric autism:** Around 7.0 million U.S. children aged 3 to 17 and 15.5 million U.S. adults currently have ADHD, and 56% of U.S. adults with ADHD were not diagnosed until age 18 or older.
- **The same unmet need:** As in autism, there is no objective test for ADHD. Diagnosis relies on interviews and rating scales, comprehensive U.S. assessments cost US$2,500 to US$5,000, and waits in Australia can reach two years.
- **A care model already going digital:** 46% of U.S. adults with ADHD have used telehealth for ADHD services. A smartphone-based Dx2 could add objective data to these established remote workflows.
- **Leverage of existing infrastructure:** Dx2 uses the same smartphone technology as Dx1 and is expected to follow the same FDA 510(k) pathway, using BlinkLab's existing CRO relationship (IQVIA-MCRA), regulatory advisers, quality management system and clinical network.
- **Beyond diagnosis:** The Company believes its biomarkers may measure individual ADHD symptom domains (hyperactivity, inattention and impulsivity) and severity, and potentially track treatment response, which could support pharmaceutical companies seeking objective endpoints for ADHD clinical trials and better therapy compliance rates. BlinkLab also intends to investigate ADHD diagnosis in adults.

During the Quarter, BlinkLab commenced preparations for the Dx2 U.S. program. The Company currently expects to start a U.S. pre-FDA pilot study in Q2 CY2027 and complete it in 2H CY2027, followed by a Dx2 pivotal study and FDA submission in CY2028, subject to regulatory engagement and successful completion of the pilot.

FDA 510(k) Pivotal Study for Dx1 Progressing to Plan

The Company continued the main phase of its U.S. FDA 510(k) pivotal validation program for BlinkLab Dx1 throughout the Quarter.[3] The prospective, multicentre, double-blinded study is being conducted by CRO partner IQVIA across leading U.S. autism centres. During the Quarter, the University of Pennsylvania site ceased participating after its principal investigator accepted a position at another university. The University of Arkansas site also stepped away from the study. Both sites were replaced by Indiana University School of Medicine. Indiana University School of Medicine is

[2] *BlinkLab Corporate Presentation (October 2026) – available through https://www.blinklab.org/investors/media-and-resources*

[3] *ASX Announcement (24 March 2026) – "BlinkLab Commences Pivotal Validation Program for FDA 510(k) Submission: First Participant Enrolled"*

affiliated with Riley Children's Autism Spectrum and Development Disorders Outpatient Program, which provides comprehensive autism assessment and treatment for children from birth to age 18 and participates in autism research. Indiana indicated capacity to recruit at least more children than the two departing sites combined and joint highest among the sites listed.

At a formal meeting in October 2025, the FDA agreed with BlinkLab's pivotal study design and confirmed a minimum performance threshold of >65% sensitivity and >65% specificity for clearance. For reference, the Dx1 U.S. pilot study achieved 84% sensitivity and 85% specificity in 485 children.[4]

The Company's timetable remains unchanged:

Milestone	Expected timing
Complete Dx1 pivotal study	Q4 CY2026
Submit pivotal study results to the FDA (and CE/MDR)	Q1 CY2027
FDA response on 510(k) clearance	Q2 CY2027

BlinkLab Presents at NSSpain, a Leading International Apple Developer Conference

During the quarter, the Company announced that Alexey Antonov, Head of iOS Development, had been invited to speak at NSSpain XIV 2026, held 16 to 18 September 2026 in Logroño, Spain.[5] NSSpain is one of the longest-running international conferences for Apple platform engineering, attracting senior iOS and macOS developers, including current and former Apple engineers.

Mr Antonov's talk, "How to Prepare Your iOS SaMD for FDA Submission", drew on BlinkLab's own experience building and documenting the Dx1 iOS application as a regulated Software as a Medical Device (SaMD), including documentation, quality management, testing strategy, and privacy and security controls. The engagement showcased BlinkLab's regulatory and engineering capability to a specialist international audience and supports recruitment as the Company grows its technical team ahead of FDA submission.

Ongoing Research Programs Beyond Paediatric Autism and ADHD

In addition to Dx1 and Dx2, BlinkLab is running nine exploratory clinical programs with leading academic partners across neurodevelopment, adult neurology and pharmacological treatment monitoring.[6] Four programs are expected to return results in Q4 CY2026 and five in CY2027. These programs use the Company's research-use platform, BlinkLab Cortex, and are designed to identify where BlinkLab's neurometrics can add value beyond diagnosis. They are not intended to support regulatory submissions at this stage.

[4] *ASX Announcement (22 October 2025) – "Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial"*

[5] *ASX Announcement (17 September 2026) – "BlinkLab Head of iOS Development to Present at NSSpain, a Leading International Apple Developer Conference"*

[6] *ASX Announcement (14 July 2026) – "Company Update on Clinical Development Programs Beyond Paediatric Autism"; recruitment status per BlinkLab Corporate Presentation (October 2026)*

Four programs have now completed recruitment. The Q4 CY2026 readouts will provide the first data on BlinkLab's performance in adults with autism, in early dementia and in monitoring pharmacological response. Together with the ADHD results, these programs support the Company's view that its reflex-based neurometrics can serve as objective, remote and repeatable endpoints for pharmaceutical and academic clinical development.

Program	Collaborator	Expected readout
Neurodevelopment		
Adult autism diagnostic assessment	VU Amsterdam	Q4 CY2026
Adult autism and lifestyle monitoring	Erasmus MC / internal	Q4 CY2026
Genetically defined autism	SHANK2 Foundation	Q1 CY2027
Paediatric autism and nutrition	ESPOCH (Ecuador)	Q2 CY2027
Paediatric and adult autism and ADHD deep phenotyping	Monash University	Q2 CY2027
Adult neurology		
Early dementia detection	Erasmus MC	Q4 CY2026
Spinocerebellar ataxia	Columbia University	Q1 CY2027
Treatment monitoring		
Pharmacological intervention with ketamine	Monash University	Q4 CY2026
Pharmacological intervention (APDS)	Erasmus MC	2H CY2027

BlinkLab also continued to progress its participation in the Kingdom of Morocco's nationwide government-funded autism screening program, announced during March 2026 quarter[7], under which BlinkLab retains ownership of the data and intellectual property. The program was subsequently launched on 22 October 2026.[8]

Corporate

Appointment of Dr Raphael Bernier as Non-Executive Director

On 8 September 2026, the Company announced the appointment of Dr Raphael Bernier as a Non-Executive Director.[9]

[7] *ASX Announcement (23 March 2026) – "BlinkLab Selected for Morocco's Nationwide Government-Funded Autism Screening Program"*

[8] *ASX Announcement (22 October 2026) – "Formal Commencement of the Nationwide Autism Screening Program in Morocco"*

[9] *ASX Announcement (8 September 2026) – "Former Apple Health Clinical Lead Appointed to Board"*

Dr Bernier recently retired from Apple Health, where he was Clinical Lead for Mental Health and led clinical development of the Mental Wellbeing app for iPhone, iPad and Apple Watch. Before Apple, he was Executive Director of the Seattle Children's Autism Center, one of the largest autism clinical programs in the United States, and held the William J. and Lydia N. Gumerman Endowed Chair in Child Psychiatry at the University of Washington. He has authored more than 200 scientific articles and two books, been cited over 36,000 times, and served as principal or co-investigator on more than 40 NIH and foundation-funded studies. He remains an active clinician and faculty member at the University of Washington.

The appointment comes at a pivotal point in BlinkLab's development, and the Board sees it shaping the Company's next phase in several ways:

- **From clearance to clinical adoption:** BlinkLab's U.S. strategy is a specialist-first launch, starting with paid lighthouse deployments at 8 to 12 specialist centres to demonstrate throughput, clinical utility and return on investment for providers. Dr Bernier has run exactly the kind of clinic Dx1 is designed to support, with first-hand understanding of its workflows, specialist capacity constraints and waiting-list pressures.
- **Digital product at scale:** His experience translating clinical science into consumer-grade digital health products at Apple is directly relevant to deploying a smartphone-based medical device across health systems.
- **Key opinion leader (KOL) engagement:** His network across autism clinicians, research institutions, health systems and technology leaders strengthens BlinkLab's KOL-led commercial model, in which the clinicians who validate the technology also become its earliest adopters.
- **Beyond autism:** His background across neurodevelopmental disorders broadly is relevant as BlinkLab extends the platform into ADHD and other indications.

Concurrently, Dr Richard Hopkins stepped down as Non-Executive Director after serving on the Board since May 2022.

Ongoing Global Investor Engagement

BlinkLab continued to build its profile with investors and the scientific community across the Asia-Pacific and, increasingly, the United States. Subsequent to the end of the Quarter:

- **Spark+ Aussie Equities Day, Singapore (9 October 2026):** Chairman Brian Leedman presented at Marina Bay Sands to more than 200 investors from across the Asia-Pacific and the United States.[10] The Company released an updated corporate presentation in conjunction with the event.
- **Simons Foundation Autism Research Initiative (SFARI) workshop, New York (13 to 14 October 2026):** Dr Boele was re-invited to SFARI's workshop series on quantitative behavioural phenotyping in autism from video footage, following his presentation at SFARI in January 2026. The series is exploring a potential multi-year collaborative effort in the field.

[10] *ASX Announcement (9 October 2026) – "BlinkLab to Present at Spark+ Aussie Equities Day Singapore"*

SFARI is one of the world's leading autism research initiatives, supporting more than 300 investigators worldwide.[11]

- **ThinkEquity Conference, New York (15 October 2026):** Dr Boele presented BlinkLab to institutional and accredited investors at the 2026 ThinkEquity Conference at the Mandarin Oriental, New York.[11]

Investor interest in BlinkLab reflects the convergence of two of the strongest themes in healthcare investing. Autism has become one of the most closely watched areas in healthcare: U.S. prevalence has risen to around 1 in 36 children, the average wait for an autism assessment exceeds two years, and autism now accounts for 41% of all participants in Australia's NDIS.[12] At the same time, investors are actively seeking exposure to artificial intelligence applied to healthcare where it delivers measurable clinical value.

BlinkLab sits squarely at that intersection, and its proposition is distinctive among listed companies. It offers an objective, AI-powered biomarker in a field that still relies on subjective behavioural assessment, delivered on a smartphone rather than specialised hardware. Its core science was invented and published by its founders at Princeton University and is protected by a granted U.S. patent. Its lead product is in an FDA 510(k) pivotal study after a positive U.S. pilot, and the platform now extends to ADHD. Pivotal study completion, FDA submission and an FDA response are all expected within the next three quarters.

Presenting at a leading autism research workshop and a U.S. investor conference in the same week illustrates BlinkLab's positioning: its credibility is built in the scientific community, and its story resonates with capital markets. As the Company approaches FDA submission and a U.S. commercial launch, broadening awareness among U.S. investors is a priority.

Financial

September Quarter Cash Flows

As of 30 September 2026, BlinkLab reported a cash balance of A$16.2 million.

For the September Reporting Period, BlinkLab reported net cash used for operating activity of A$1.802 million, with expenditure for the Quarter primarily used for research and development on the Company's platform and costs associated with support for its ongoing research and FDA clinical study programs (A$1.330 million). Administration and corporate costs of A$500k were attributable to year-end audit costs, ASX listing costs, and operational expenses.

Related Party Payments

In accordance with ASX Listing Rule 4.7C.3 for related party payments, the Quarter included payments of A$0.208 million comprising Directors fees and superannuation.

[11] *ASX Announcement (13 October 2026) – "BlinkLab to Present at Simons Foundation and ThinkEquity in New York City"*

[12] *BlinkLab Corporate Presentation (October 2026) – available through https://www.blinklab.org/investors/media-and-resources*

Outlook

The coming quarters are expected to be the most milestone-rich in BlinkLab's history, as the Company moves from clinical development towards regulatory clearance and commercialisation. Near-term priorities include:

- **Dx1 pivotal study completion (Q4 CY2026):** Completing recruitment and testing in the FDA 510(k) pivotal study, followed by submission of results to the FDA and progression of European CE/MDR regulatory clearance in Q1 CY2027. An FDA response on 510(k) clearance is targeted for Q2 CY2027.
- **Commercial readiness for Dx1:** Preparing for a specialist-first U.S. launch, including workflow and site agreements, pricing, and health economics and outcomes research to build the evidence base for reimbursement from first commercial use. The pivotal study sites are expected to be BlinkLab's first customers at launch, subject to FDA clearance.
- **Dx2 U.S. program:** Finalising CRO engagement, protocols and site onboarding for the Dx2 U.S. pre-FDA pilot study, expected to commence in Q2 CY2027.
- **Research readouts:** Four exploratory readouts expected in Q4 CY2026: adult autism diagnostic assessment (VU Amsterdam), adult autism and lifestyle monitoring (Erasmus MC), early dementia detection (Erasmus MC) and ketamine treatment monitoring (Monash University), with five further readouts in CY2027.
- **Morocco:** Continuing to progress the nationwide autism screening program in the Kingdom of Morocco as a reference point for scalable use of BlinkLab's platform.

This announcement has been authorised for release by the Board of BlinkLab Limited.

For further information please contact:

Dr Henk-Jan Boele
Managing Director & CEO
henkjan@blinklab.org
M: +31 (0) 611 132 247

Brian Leedman
Non-Executive Chairman
brian@blinklab.org
M: +61 (0) 412 281 780

About BlinkLab Limited

BlinkLab Limited was founded by neuroscientists at Princeton University and is developing a smartphone-based diagnostic platform for autism. Its most advanced product, BlinkLab Dx1, is an autism diagnostic aid for clinicians that leverages smartphones, artificial intelligence, and machine learning to capture objective, reflex-based measures, supporting earlier and more accurate autism identification. This enables timely intervention during critical periods of brain development. BlinkLab is led by an experienced management team and Board with deep expertise in digital healthcare, computer vision, and AI, supported by a Scientific Advisory Board of leading experts in autism and brain development.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
BlinkLab Limited	
ABN	**Quarter ended ("current quarter")**
53 652 901 703	30 September 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(1,330)	(1,330)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	(84)	(84)
	(d) leased assets	-	-
	(e) staff costs	(52)	(52)
	(f) administration and corporate costs	(500)	(500)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	164	164
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(1,802)**	**(1,802)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(11)	(11)
	(d) investments	-	-
	(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
	(f) other non-current assets	(325)	(325)
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(336)**	**(336)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	119	119
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	313	313
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(3)	(3)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Payment of lease liability	(29)	(29)
3.10	**Net cash from / (used in) financing activities**	**400**	**400**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	17,953	17,953
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,802)	(1,802)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(336)	(336)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	400	400
4.5	Effect of movement in exchange rates on cash held	(4)	(4)
4.6	**Cash and cash equivalents at end of period**	**16,211**	**16,211**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,994	2,883
5.2	Call deposits	14,217	15,070
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**16,211**	**17,953**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(208)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**		

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,802)
8.2	Cash and cash equivalents at quarter end (item 4.6)	16,211
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	16,211
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**9.00**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 29 October 2026

Authorised by: The Board of BlinkLab Limited

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.